What is HC Wainwright’s Estimate for ITRM FY2026 Earnings?

Iterum Therapeutics plc (NASDAQ:ITRMFree Report) – HC Wainwright increased their FY2026 earnings estimates for shares of Iterum Therapeutics in a research report issued on Thursday, June 12th. HC Wainwright analyst M. Keller now expects that the company will earn $0.10 per share for the year, up from their prior forecast of $0.06. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Iterum Therapeutics’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Iterum Therapeutics’ FY2027 earnings at $0.75 EPS.

Iterum Therapeutics (NASDAQ:ITRMGet Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14).

Iterum Therapeutics Stock Performance

Shares of NASDAQ ITRM opened at $0.99 on Friday. Iterum Therapeutics has a 52-week low of $0.81 and a 52-week high of $3.02. The firm has a 50 day moving average price of $1.04 and a two-hundred day moving average price of $1.42. The stock has a market cap of $39.64 million, a P/E ratio of -0.76 and a beta of 2.78.

Hedge Funds Weigh In On Iterum Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lee Financial Co acquired a new stake in shares of Iterum Therapeutics during the fourth quarter worth $28,000. Sanctuary Advisors LLC bought a new position in shares of Iterum Therapeutics in the fourth quarter valued at $35,000. Citadel Advisors LLC bought a new position in shares of Iterum Therapeutics in the fourth quarter valued at $38,000. Two Sigma Investments LP bought a new position in shares of Iterum Therapeutics in the fourth quarter valued at $45,000. Finally, OneDigital Investment Advisors LLC bought a new position in shares of Iterum Therapeutics during the first quarter valued at about $124,000. 9.21% of the stock is currently owned by institutional investors and hedge funds.

About Iterum Therapeutics

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Recommended Stories

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.